These veterans may be the future of cannabis-based pharmaceuticals
Blake speaks with Army veteran turned co-founder and CEO of RMR Laboratories, Mike Lui, about his over-the-counter cannabis pharmaceutica...
Our first product line targets chronic pain and sports injuries using CBD, which is non-psychoactive.
1 in 3 people in the United States suffer from chronic pain.
We decided to start with these applications because we saw an overwhelming need to develop a natural, effective alternative to pain killers with negative side effects, like opioids.
Here’s is a sample of what they’ve had to say:
The shortest duration of relief was 90 minutes. Some people had their pain go away completely after continued use. Every single trial user felt some type of pain relief.
The top layer of the skin, called the stratum corneum, is designed to protect the body by keeping harmful substances out.
The topicals designed by RMR Laboratories work by creating an intercellular pathway directly through the skin. The pharmaceutical technology has been shown to deliver active ingredients up to 25 millimeters below the skin in a non-toxic, non-traumatic way.
Our skin-penetrating technology provides a platform to quickly and efficiently address new health applications as well as build depth within current product lines.
We have only begun to scratch the surface on the therapeutic effects of different delivery systems and cannabis strains. In addition to topicals, we have future plans to expand into additional health and wellness product categories.
Our topicals address the source of the muscle or joint inflammation rather than try to mask the pain like existing pain relief creams do. NSAIDS can cause unwanted side effects like stomach irritation. Finally, unlike opioids, our pain relieving topicals have a localized effect, are not psychoactive (in the case of CBD), and are convenient to use because they do not impair motor function.
Our first three markets for product launch will be in Colorado, Oregon, and California. We are currently finalizing pre-orders from these three markets for $2.2M in revenue in the first half of 2018.
Our exclusive partnership with Advanced Nutrients for production and distribution expands our reach into every major market for medical and recreational cannabis, both in the US and internationally.
Our operating model allows us to scale quickly and efficiently. We centralize our research and production in California and ship the formula base without cannabis actives to each market where the end products are produced.
The proceeds from the campaign will be used on three priorities:
I believe in the power of high expectations on the performance of people and teams. I believe that everyone has a ceiling that they cannot see, but if they continue to strive and persevere, that high ceiling may come into view. That's why I believe in the power of the work we are doing at RMR Laboratories. If we can develop products to reduce people's pain in a meaningful way without paralyzing addictions or side effects, then we've given them a chance to set and strive for those high expectations.
Thank you for taking some time to learn about the work we are doing at RMR. I'm proud of the progress the team has made in such a short period of time. Our first flagship CBD formulation has garnered tremendous response from our trial participants and I can't wait to make it available to all those that experience chronic pain.
But we're just getting started, and I'm just as excited about the rest of our roadmap. We finally have the ability to use clinically valid transdermal technology to steer the healing properties of cannabis to where we need it. That to me is game-changing.
I hope you'll join us.
The smallest investment amount that RMR Laboratories is accepting.
RMR Laboratories needs to reach their minimum funding goal before
the deadline. If they don’t, all investments will be refunded.
The Crowd SAFE is an agreement for future equity in the startup,
meaning that it can convert to equity in the future.
The Crowd SAFE is an agreement for future equity in the startup, meaning that it can convert to equity in the future.
$50,000 – $1,070,000
RMR Laboratories needs to raise
before the deadline. The maximum amount RMR Laboratories is willing
to raise is $1.07M.
This is the most common question that we receive. The short answer is yes. If our topicals contain THC, you will receive a psychoactive effect from it and you will test positive on a drug test. For the first products we are launching in 2018 targeting chronic pain and sports injuries, the formulations contain only CBD, which is not psychoactive, and you will not get ‘high’.
Our roadmap for topicals is extensive and we have not even scratched the surface with regards to the health applications we can address. Having said that, we are also in the process of exploring other delivery systems and health and wellness categories, like nasal and sublingual sprays. One thing that we are not currently pursuing however is any edible or smoked products.
Chronic pain is officially defined as an unpleasant sense of discomfort that persists or progresses over a long period of time that is often resistant to medical treatments. On the other hand, acute pain suddenly arises in response to a specific injury, like a broken arm.
Our products contain active ingredients derived from cannabis and are subject to the regulations that cover those ingredients when it comes to interstate travel. We advise you consult with your local state and federal laws as appropriate.
Our products contain all natural ingredients that adhere to stringent quality standards. If you have any doubt, we advise you consult your medical professional prior to starting any new course of therapy.
No, our products are over-the-counter.
Chronic pain differs in severity and source. The short answer is to apply when you are feeling pain and proactively if you know what triggers your pain - for example, we have athletes apply to their knees prior to a run. You can reapply as needed.
Specific to transdermal delivery, it represents a true revolution. It's more efficient with active ingredients (you need less, which lowers product COGS), more consistent (because it takes a direct path), and creates more options for product development (because you remove a huge barrier to bodily absorption). Specific to other delivery methods - oral, needle - it's less traumatic, but also these other delivery methods serve other purposes.
RMR Laboratories successfully raised $784,479 from 952 investors on December 31, 2017
This product has a great potential in the market place.James BunchInvested over 1 year ago
I think the medical marijuana business is important and has potential for profitEdward WallInvested over 1 year ago
I am a big believer in medical marijuana and it's profit potential.Loren RosethInvested over 1 year ago
I believe in the power of the cannabis plant to cure and help people in pain.Bruno RochaInvested over 1 year ago
I belive in this industry and its growth potentialganesh raoInvested over 1 year ago
I believe that medical/recreational marijuana market has an enormous potential for the future. RMR has the experience, background, and people to be a winnerHarsha RaoInvested over 1 year ago
Unkowm space, learning opportunity.Diego GomesInvested over 1 year ago
I believe in RMR's potential.Hoon TanInvested over 1 year ago
I see potential in the delivery system and I have chronic pain so I am hoping for successDustin StarbuckInvested over 1 year ago
I like the idea of safe, effective natural pain relievers.Robert HerzfeldInvested over 1 year ago
Investors should verify any issuer information they consider important before making an investment.
All securities-related activity is conducted by OpenDeal Portal LLC doing business as Republic, a funding portal which is registered with the US Securities and Exchange Commission (SEC) as a funding portal (Portal) and is a member of the Financial Industry Regulatory Authority (FINRA). Republic is owned by OpenDeal.
Investments in private companies are particularly risky and may result in total loss of invested capital. Past performance of a security or a company does not guarantee future results or returns. Only investors who understand the risks of early stage investment and who meet the Republic's investment criteria may invest.
Republic does not verify information provided by companies on this Portal and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Portal can be found by searching the EDGAR database.